PL332496A1 - Liquid alendronate preparations - Google Patents

Liquid alendronate preparations

Info

Publication number
PL332496A1
PL332496A1 PL97332496A PL33249697A PL332496A1 PL 332496 A1 PL332496 A1 PL 332496A1 PL 97332496 A PL97332496 A PL 97332496A PL 33249697 A PL33249697 A PL 33249697A PL 332496 A1 PL332496 A1 PL 332496A1
Authority
PL
Poland
Prior art keywords
preparations
alendronate
liquid
liquid alendronate
alendronate preparations
Prior art date
Application number
PL97332496A
Inventor
Maneesh J Nerurkar
William A Hunke
Drazen Ostovic
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PL332496A1 publication Critical patent/PL332496A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL97332496A 1996-10-04 1997-10-02 Liquid alendronate preparations PL332496A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (1)

Publication Number Publication Date
PL332496A1 true PL332496A1 (en) 1999-09-13

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97332496A PL332496A1 (en) 1996-10-04 1997-10-02 Liquid alendronate preparations

Country Status (20)

Country Link
EP (1) EP1007054A4 (en)
JP (1) JP2001501222A (en)
CN (1) CN1238691A (en)
AU (1) AU723357B2 (en)
BG (1) BG103306A (en)
BR (1) BR9712197A (en)
CA (1) CA2267370A1 (en)
CZ (1) CZ116999A3 (en)
EA (1) EA001213B1 (en)
EE (1) EE03669B1 (en)
HU (1) HUP0000125A3 (en)
IL (1) IL129127A0 (en)
IS (1) IS5012A (en)
NO (1) NO991569L (en)
NZ (1) NZ334836A (en)
PL (1) PL332496A1 (en)
SK (1) SK42999A3 (en)
TR (1) TR199900730T2 (en)
WO (1) WO1998014196A1 (en)
YU (1) YU17499A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116865B8 (en) 2001-01-23 2021-05-25 Gador Sa composition comprising bisphosphonates for the prevention and/or treatment of metabolic bone diseases, process for preparing such composition and use thereof
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
JP2010043119A (en) * 2009-10-16 2010-02-25 Gador Sa Composition for preventing and/or treating bone metabolic disease, method of preparing the same and use thereof
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
BR9712197A (en) 1999-08-31
AU4644897A (en) 1998-04-24
NO991569L (en) 1999-06-04
WO1998014196A1 (en) 1998-04-09
HUP0000125A2 (en) 2000-06-28
IL129127A0 (en) 2000-02-17
TR199900730T2 (en) 1999-07-21
EE9900113A (en) 1999-10-15
HUP0000125A3 (en) 2001-04-28
EE03669B1 (en) 2002-04-15
JP2001501222A (en) 2001-01-30
AU723357B2 (en) 2000-08-24
NO991569D0 (en) 1999-03-30
IS5012A (en) 1999-03-26
EP1007054A4 (en) 2000-07-19
SK42999A3 (en) 2000-01-18
CN1238691A (en) 1999-12-15
CA2267370A1 (en) 1998-04-09
EA001213B1 (en) 2000-12-25
NZ334836A (en) 2000-11-24
YU17499A (en) 1999-11-22
CZ116999A3 (en) 1999-09-15
BG103306A (en) 2000-01-31
EP1007054A1 (en) 2000-06-14
EA199900352A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
GB9613858D0 (en) Hydrophobic preparations
PL333376A1 (en) Connection cubicle
ZA974486B (en) Concentrated antibody formulation
DE69804447D1 (en) Lithographisches system
GB2311865B (en) Liquid metering
GB2314592B (en) Dispensing system
PL332496A1 (en) Liquid alendronate preparations
SG52872A1 (en) Liquid redistribution system
PL340555A1 (en) Preparations containing dissolved paroxetin
PL325324A1 (en) Heasting system
GB9720729D0 (en) Liquid heating system
GB9701659D0 (en) Irrigation system
GB2292278B (en) RF System
ZA963510B (en) New liquid formulations
GB9410081D0 (en) Liquid distribution system
GB9621401D0 (en) Liquid steriliser
GB9715487D0 (en) Mearsurement system
GB2319169B (en) Liquid applicator
GB2320149B (en) Modulators
GB9517671D0 (en) Application shari8ng system
GB9700541D0 (en) Liquid alendronate formulation
GB9414780D0 (en) Liquid application system
GB9603938D0 (en) Liquid spraying
GB9426350D0 (en) Liquid dispeser
GB9721325D0 (en) Cleaning preparations